New Zealand markets open in 1 hour

Pyxis Oncology, Inc. (PYXS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.7600+0.0200 (+0.53%)
At close: 04:00PM EDT
3.8400 +0.08 (+2.13%)
After hours: 04:48PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.7400
Open3.7500
Bid3.7400 x 300
Ask3.7800 x 300
Day's range3.6900 - 3.9700
52-week range1.3500 - 6.8500
Volume234,066
Avg. volume583,990
Market cap221.421M
Beta (5Y monthly)1.45
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

    BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings. A

  • GlobeNewswire

    Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

    PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial

  • GlobeNewswire

    Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

    BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Tuesday, May 14, 2024 at 3:05 PM ET at the RBC Capital Markets Global Healthcare Conference, where members of management will also host investor one-on-one meetings. A live webcast and